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ABSTRACT 
 
Borderline Personality Disorder is a commonly diagnosed personality disorder 
characterized by marked emotional dysregulation, and is associated with impairments 
in self-functioning and interpersonal relationships. With a high mortality rate and 
elevated healthcare costs, this disorder has been the subject of numerous investigations 
in the past few years, namely concerning its etiology and development. It is somewhat 
established that borderline personality traits have a hereditary component of 
transmission, and genes involved in the serotoninergic and glutamatergic 
neurotransmission systems, as well as in the hypothalamic-pituitary axis, have been 
implicated in the disorder. On the other hand, environmental influences such as history 
of childhood abuse, neglect, trauma, and sociocultural variables have also been 
suggested to play a part in its etiology. Recent research has pointed to possible 
interactions between the genetic and environmental fields, either by additive effects or 
by modulating one another. This work intends to review the studies published in the 
last few years concerning this area, and to point possible directions for future research. 
 
KEYWORDS: borderline personality disorder; gene-environment interaction; genetic 
predisposition to disease; environment; risk factors 
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INTRODUCTION 
 
Over the last few years, there has been some controversy as to whether the 
diagnosis of a personality disorder (PD) should be based on categorical or dimensional 
criteria. A strong argument in favor of the latter is the absence, to date, of a non-
arbitrary cut-off point on the continuum between normal and extreme positions on 
behavior dimensions.1 The new Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5), although retaining the categorical approach of its predecessor, also includes 
an alternative hybrid dimensional-categorical model for diagnosis of personality 
disorders in a separate chapter. The manual defines the essential features of a PD as “an 
impairment in self and interpersonal functioning” associated with “pathological 
personality traits”, translating into a pattern of behavior not better understood as 
socially normative and which is stable across time and situations.2 
With this in mind, Paris and Lis describe personality disorders as arising from a 
combination of trait vulnerability, individual experiences and social expectations. 3 
However, an unusual trait profile does not necessarily mean that symptoms will 
develop: a key aspect of personality disorders is poor adaptation to the surrounding 
environment. Maladaptation can either be the outcome of a pattern of extreme, 
intransigent behaviors, the result of harmful environmental influences – or even an 
association of both.1 
According to traditional personality theory, an individual’s personality becomes 
somewhat stable after reaching adulthood4, but the features that shape it may come into 
play before that, with early relationships serving often as a template for long-term 
patterns of interpersonal and adaptive (or maladaptive) behaviors.5 A model for the 
development of personality disorders suggests a possible interplay between inherited 
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vulnerability (as expressed by personality traits) and environmental factors such as 
childhood abuse and neglect.6 Social factors like family and school environment, as we 
will discuss later in this paper, may also exert some influence in the process. 
Of all the personality disorders, Borderline Personality Disorder (BPD) stands out 
among the rest. With a prevalence of 1-2% in the general population, up to 10% in 
psychiatric outpatients and 20% in psychiatric inpatients, BPD is the most commonly 
diagnosed PD7, and individuals affected by the disorder require more healthcare 
resources than patients with other psychiatric diagnoses.8 According to DSM-5, the core 
features of BPD include an impairment of self-image or lack of self-direction, unstable 
and intense interpersonal relationships, and personality traits characterized by 
negative affectivity, antagonism, and impulsive or risk-taking behaviors.2 Mortality 
among BPD patients is high because of suicide and impulsive behavior; up to 10% of 
BPD patients commit suicide, a percentage nearly 50 times higher than in the general 
population.9 It is more frequently diagnosed in women than in men7 and it has a 
substantial comorbidity with substance abuse, mood disorders, anxiety disorders, and 
other PDs.10 
As other personality disorders, BPD is assumed to be the outcome of complex 
interactions between genetic, neurobiological and environmental factors, and a good 
example of the connection between the biological and psychosocial areas.6,11 There 
appears to be a familial component of transmission, with estimates of hereditability 
around 42%12 and a higher risk of development in relatives of BPD or major depression 
patients.13,14 This genetic predisposition has been hypothesized as translating 
disturbances in the serotoninergic, glucocorticoid and/or glutamate neurotransmission 
systems.10,11,15 On the other hand, BPD patients have been notably associated with a 
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childhood experience of abuse, neglect, environmental instability, poor parental care 
and parental psychopathology.16,17 
The connection between these two fields has been recently discussed in the 
literature. Perroud et al. have hypothesized that long-term epigenetic changes may 
result from childhood abuse and neglect18, possibly mediating the transition to 
psychopathology later in life. Linehan’s biosocial model describes impulsivity and 
emotional vulnerability as biological risk factors for the child to develop BPD, which 
may then interact with an invalidating familial environment to develop and perpetuate 
a pattern of emotional dysregulation. A child with a tendency toward certain behavior, 
as an effort to deal with a difficult environment, develops more and more extreme 
patterns of dysfunction.19 
Whether or not the genetic inheritance is sufficient to develop BPD independently 
of childhood conditions, or vice-versa, is still an area of debate. This work reviews the 
state of the art in genetic and environmental contributions to BPD etiology, as well as 
possible interactions between the two grounds. 
 
METHODS 
 
The purpose of this work was to evaluate the genetic and environmental influence 
in the etiology of Borderline Personality Disorder. To do so, I resorted to the US 
National Library of Medicine’s PubMed database using Thomson Reuters’ Endnote X7 
software. A search was conducted for all articles published in 2000 or after which 
included the following combinations of terms in their abstracts: “gene environment 
personality disorders”, “borderline personality gene” and “borderline personality 
environment”. Additionally, I also searched for articles that included the combination of 
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words “gene environment personality” in the title. In total, 37 articles were collected 
using this method. Upon reading of the abstracts, 9 of these articles were excluded: 3 
because they were in a language other than English, and 6 because they did not seem 
related to the work. The remaining 28 articles were included based on their relevance. 
After reading the selected articles I was able to detect a number of works that 
were either consistently quoted or potentially important to my work. As such, an 
additional 19 articles were included in the study, regardless of publication date. 
In total, 47 articles were reviewed for this work. 
 
HERITABILITY: THE GENETIC INFLUENCE IN BORDERLINE PERSONALITY 
DISORDER 
 
The amount of phenotypic differences between individuals in a specific population 
that can be due to genetic dissimilarities is called heritability. In the classical twin 
model, the total variance in a phenotype is divided into additive genetic influence, 
shared environment and non-shared (i.e., individual-specific) environment.20 
Personality traits have been reported as being influenced by genetic factors, with 
heritability estimates of approximately 42%.12 Genetic effects in personality are mainly 
additive, with different alleles or loci acting in an additive way to increase the risk for a 
disorder or trait. However, non-additive contributions have also been demonstrated, 
with alleles interacting with other alleles in the same locus (dominance) or in other loci 
(epistasis). Shared environment includes all environmental circumstances or exposures 
that contribute to similarity between twins, and is usually found to be of minor 
importance in personality.20 Non-shared environment is what makes the twins 
different, and will be discussed elsewhere in this work. 
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While the model of genetic interactions in personality development may seem 
complex, the case of BPD might be even more so. Distel et al. showed that although BPD 
features are genetic in origin and influenced by the same genes in different ages, they 
are only partly transmitted to offspring because they require combinations with other 
genes in order to develop BPD, and these combinations may not be shared by parents 
and their children.21 
A number of neurotransmitters and systems have been suggested to play a role in 
BPD etiology, including serotonin, glutamate and the hypothalamic-pituitary axis 
(HPA).10,11,15,22,23 Of these, serotonin (5-HT) is the one whose involvement is more 
extensively documented. The exact dysfunction is nevertheless still elusive, with 
polymorphisms of a number of genes responsible for different steps in 5-HT metabolism 
and signaling cascade being found in BPD patients. 
One of them is the serotonin transporter (5-HTT) gene. The 5-HTT gene-linked 
polymorphic region (5-HTTLPR) is one of the most commonly used polymorphic 
markers, with a short (s) allele associated with reduced transcriptional efficiency when 
compared to the long (l) variant. This leads to a decline in 5-HT reuptake in the 
presynaptic neuron and may be involved in emotional dysregulation.24 
Ni et al. tested the association between variants of the 5-HTT gene and BPD in 89 
Caucasian BPD patients and 269 Caucasian healthy controls. The group used the 5-
HTTLPR and another marker, the intron 2 variable number of tandem repeats (VNTR). 
It is speculated that VNTR may play a role as a transcriptional enhancer of the 5-HTT 
gene with particular importance in brain development and synaptic plasticity, and the 
10-repeat acts as a weaker enhancer than the 12-repeat.15,25 They reported a higher 
frequency of the 10-repeat VNTR haplotype, a lower frequency of the 12-repeat and a 
higher genotype frequency with 10-repeat in BPD patients when compared to healthy 
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controls.15 While they did not find a strong association between 5-HTTLPR and BPD, 
their results supported a possible combined effect of VNTR and 5-HTTLPR in 5-HT gene 
expression.15 In 2008, Pascual et al. failed to replicate this finding, but it is pertinent to 
mention that, although the controls had no history of psychiatric illness, they were not 
screened to exclude BPD.26 In 2011, Blom et al. studied the relationship between the 
two 5-HTTLPR alleles and personality disorder traits, and they also did not find a 
significant association between 5-HTTLPR and BPD.27 
Another study found an association between the short (s) allele and BPD and 
antisocial personality disorder (APD) traits. With the results of Ni et al. in mind, the 
authors theorized that the 5-HTTLPR s-allele may be responsible for a broader 
endophenotype for impulsive, self-damaging and other-damaging behaviors, common to 
both borderline and antisocial personality disorders.28 
The proposal that 5-HTTLPR does not play an independent role in BPD etiology 
but may be involved in gene-gene interactions is supported by Tadic and associates. The 
group studied the role of 5-HTT and catechol-O-methyl transferase (COMT) in BPD 
etiology, using 5-HTTLPR and a COMT functional single-nucleotide polymorphism (SNP 
Val158Met). The results revealed no significant difference in s/l genotype distribution 
between BPD patients and controls, but there was a significant gene-gene interaction 
between the short allele for 5-HTTLPR and COMT Met158, increasing susceptibility for 
BPD.29 
While these studies were conducted using adult samples, Hankin et al. tested if the 
association of 5-HTTLPR and BPD traits could also be found in youth. The results 
indicated that children and adolescents carrying one or two copies of the s-allele of 5-
HTTLPR displayed higher levels of BPD traits. Moreover, discriminant validity analyses 
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revealed that 5-HTTLPR was linked specifically with BPD traits but not with depressive 
symptoms, often found overlapping with BPD traits.30 
Other genes presumably involved in BPD etiology include the 5-HT receptor (5-
HTR), monoamine oxidase (MAO), tryptophan hydroxylase (TPH) and the already 
mentioned COMT genes. COMT and MAO are enzymes involved in dopamine and 
noradrenergic metabolism, and TPH is involved in serotonin synthesis.6,29 
A study from Dammann et al. found that BPD patients had increased methylation 
levels for serotonin 2A receptor (5-HTR2A), glucocorticoid NR3C1 receptor, soluble 
COMT, MAO-A and MAO-B genes in peripheral blood samples. It is unknown, however, 
whether the same pattern of methylation in these genes is found in other tissues (e.g. 
brain).10 
Other studies have failed to find an association between 5-HTR2A and BPD 
diagnosis22,31, but Ni et al. found an association between 5-HTR2A and BPD personality 
traits.22 While another variant of the 5-HT receptor, 5-HTR1B, has reportedly no 
association with BPD23,31, the 5-HTR2C variant is presumably involved in gene-gene 
interactions with the TPH2, MAO-A and 5-HTT genes, resulting in an increased risk for 
BPD.31 
Finally, in addition to the epistatic effect reported for the COMT gene, the Met158 
polymorphism also has an independent association with BPD, which suggests a role of 
dopaminergic and/or noradrenergic neurotransmission dysfunction in the etiology of 
the disorder.29 
In conclusion, although many genes seem to be involved in the development of 
borderline personality disorder, the exact mechanism is not yet known. As it appears, 
BPD arises as the outcome of a complex network of genetic interactions that do not 
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remain unchanged in the face of different environmental influences, as we will discuss 
in another section. 
 
LIFE EXPERIENCES: THE ENVIRONMENTAL INFLUENCE IN BORDERLINE 
PERSONALITY DISORDER 
 
Emotions are a fundamental part in attachment relations. If emotional 
disturbances are present, as is the case in BPD, they can exert an influence in 
relationships throughout life. Emotional and affective expression in adulthood may be 
shaped by early social experiences, with relationships with parents or caretakers 
serving as a model for future interpersonal exchanges.5 For instance, good maternal 
care in childhood was associated with high self-esteem, decreased trait anxiety and 
decreased salivary cortisol in response to stress in a sample of college students.32 
On the other hand, the environment outside the home is also important in 
personality development: a study from 2009 found a relationship between adolescent 
school climate and PD traits. Specifically, cluster B symptoms were less present in 
students of schools with higher learning focus.33 The authors speculate that the 
demands and structure of such schools would suppress the impulsive and rule-breaking 
behaviors that are characteristic of cluster B PDs. Considering that BPD matures during 
adolescence34, it is easy to believe that young people who are at risk for the disorder 
(for instance, because of emotional vulnerability) are more likely to express symptoms 
under conditions of low social cohesion or instability during this period.3 Accordingly, 
when Wang et al. screened traits from cluster A and cluster B personality disorders in 
high school students, they found that students from remarried families or with a low 
subjective perception of social status had higher borderline scores.4 This underlines the 
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importance of a well-defined role in the community, a good social support and a stable 
family environment in tempering individual susceptibility to BPD. A good network of 
role models or parental surrogates and supportive community institutions can provide 
the basis for the child to deal with the impact of adverse parent-child relationships and 
familial pathology.16 
Another important factor in BPD etiology appears to be the exposure to serious 
life events (SLEs). In fact, life experiences seem to play an important part in the 
development of BPD, with unique environmental influences being responsible for 
54,9% of the variance in borderline personality in a study of 2009.21 Several SLEs have 
been related to BPD, such as abuse, parent loss or separation, family conflict or familial 
psychopathology, or having a complicated/unusual illness during childhood.16,35,36 
While studies have been discordant about the real effect of some of these events in BPD, 
a consensus seems to exist when it comes to factors like neglect, childhood abuse and 
trauma.6,16,36,37 Moreover, the severity of abuse appears to correlate with the severity of 
BPD symptoms.38 
How these environmental stressors exert their influence on behavior and 
personality traits is still a question, and a number of possible explanations have been 
proposed. Molina et al. speculate that some BPD traits, depending on the context, can be 
viewed as adaptive or at least as having the purpose of acting as such.5 For example, as 
impulsive strategies can be useful if survival depends on a quick response (e.g. in war), 
some disruptive traits may have had a useful short-term function in helping patients 
managing environmental adversity or obtaining social aid. However, over time or in a 
context where the adverse element no longer exists, they prove themselves 
maladaptive.5 Another study states that the cognitive mechanism of thought 
suppression, often used by victims of abuse to try to deal with unpleasant memories, 
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may actually exacerbate BPD traits and contribute to the development of symptoms.39 
On the other hand, a majority of studies consider that environmental stressors do not 
act alone in increasing the risk for BPD, and instead interact with the genome in 
producing this vulnerability. In the last few years this theory has been discussed and 
tested using specific genes and SLEs, as we review in the following section. 
 
MODULATION AND SYNERGY: HOW GENES AND ENVIRONMENT CAN RELATE IN 
BORDERLINE PERSONALITY DISORDER 
 
There are three possible ways genes and environment can influence the 
susceptibility to psychopathology: by way of additive effects of both genetic and 
environmental factors, with genes controlling the sensitivity to the environment, or 
with genes controlling the exposure to the environment.40 
In the additive model, the individual’s vulnerability to a disorder is the sum of 
genetic and environmental influences. One example is the vulnerability threshold 
model, in which the risk for psychopathology (as defined by inherited susceptibility) 
increases with increased exposure to certain environmental aggressors.6,41 If an 
individual is already vulnerable for a condition because of genetic factors, even a small 
environmental insult may be sufficient for its development.41 
If the sensibility to the environment depends on the genetic background, we can 
assume that the environment wields an effect on gene expression, with specific 
“susceptibility genes” for a disorder being expressed under certain conditions or in 
response to certain life events.1,41 The diathesis-stress model, which postulates that 
environmental stressors (“stress”) contribute to BPD symptoms and traits only in the 
context of emotional and behavioral vulnerability (“diathesis”), fits in this 
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description.19,39 This model implies that a specific situation may have a bigger or 
smaller impact on the individual depending on his or her genotype.17 
Finally, if genetic background and life experiences are somehow correlated, this 
means that life experiences are determined by genetic endowment. In other words, an 
individual creates his or her own life experiences according to his genetic context and 
predisposition.17 For instance, a child who shares a predisposition to negative affectivity 
with his or her parents is also more likely to be nurtured in a hostile and abusive family 
setting. This can either be due to their shared background or because the child’s genetic 
tendency to disinhibition elicits an aggressive response by his or her parents.37 
Recent research has tried to clarify this relationship. It has been suggested that 
epigenetic mechanisms (e.g. methylation of gene promoters) are involved in 
determining resistance to stress and personality traits.1 It is interesting to observe that 
monozygotic twins share similar degrees of DNA methylation in an early age, but differ 
significantly later in life42, and we can speculate that this discrepancy is due to non-
shared experiences. 
In line with the epigenetic proposition, Perroud et al. found an increased 
methylation of the glucocorticoid NR3C1 receptor gene promoter in BPD patients 
exposed to abuse or neglect during childhood. The degree of promoter methylation was 
also significantly correlated with severity or repetitions of abuse.18 Curiously, both this 
work and another by Dammann et al.10 found an increased level of NR3C1 methylation 
in BPD patients with no history of abuse. These findings are in line with the hypothesis 
of a relationship between childhood abuse and BPD being mediated by common genetic 
and environmental factors, as described by Bornovalova and associates.37 
Grosjean et al. suggested that NMDA neurotransmission may also be implicated in 
the neurobiological consequences of environmental stressors. The NMDA pathway, 
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particularly important in brain development and neuroplasticity, is activated by stress 
hormones and can have a neurotoxic effect on brain cells. Neuronal damage may vary 
according to the intensity, duration and type of stress, and NMDA-induced 
neuroplasticity might be a key factor in susceptibility to traumatic events, as it modifies 
the neurotransmission threshold level concerning the physiological response to 
stress.11 
A study from Tadic et al., already mentioned in this article, found that the short 
allele of the 5-HTTLPR, in addition to being involved in an interaction with the COMT 
gene, also appears to have a moderating effect on other susceptibility factors for BPD 
like SLEs.29 There is also some indirect evidence supporting this effect of 5-HTTLPR: 
one study found an association between the s/s genotype and the development of 
emotional problems after experiencing bullying43, and another found an additive effect 
of the s-allele and emotional abuse in distress intolerance.44 As we saw, emotional 
dysregulation is one of the features of BPD19, and distress intolerance has been 
associated with this disorder in the past.45 
Wilson et al. also found that the A allele of the TPH1 gene, besides being more 
prevalent in BPD patients, significantly moderated the association between childhood 
abuse and BPD as an adult, with more severe abuse rendering a higher risk for the 
disorder.38 Furthermore, the increasing severity of the abuse also influenced the 
severity of the disorder, as indicated by the number of DSM-IV criteria met for BPD. 
Other genes have also been reported interacting with environmental factors in the 
development of BPD features or traits. The short/short genotype for NOS1, a gene 
linked to the serotoninergic system41, interacted with adverse family environment and 
SLEs increase impulsivity scores in males.46 Also, the dopamine D4 receptor gene 
(DRD4) interacted with socioeconomic status in determining the expression of delay 
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discounting, a behavioral endophenotype of impulsive decision-making.47 Finally, the 
correlation between SLEs and suicide, a behavior frequently seen in BPD patients, is 
reportedly mediated by genes involved in the HPA and in the 5-HT signaling system.48,49 
With this in mind, we can state it is a commonly held view that genetic liability, 
early life stress and ongoing stress define individual responsiveness to life events and 
therefore the risk for BPD.11 As discussed, when studying specific genes implicated in 
BPD etiology, variable patterns of expression can be found depending on the exposure 
to certain stressors or SLEs. When it comes to addressing the question of causality, 
however, the results to date are still uncertain.16,41 
 
DISCUSSION 
 
Reviewing the available research, we can establish that borderline personality 
disorder, in its etiology, encompasses a multitude of different factors. First we have the 
genetic inheritance of the individual, rendering him or her with a low or high 
susceptibility to psychopathology. Then, during childhood and adolescence, the 
potential triggers to a disruptive pattern of behavior and emotional dysregulation, such 
as traumatic events or abuse. The interface between the two can be one of 
interdependence, mutual regulation, or something of a slippery slope with the addition 
of multiple vulnerabilities. The behavior pattern of the BPD individual may be 
interpreted as a reaction to certain environmental stressors that, over time, has proven 
troublesome and maladaptive5, but that nonetheless depend on genetic 
predisposition.19 
As pointed by Torgersen, it is interesting to consider that both the genes and the 
environment are part of an inheritance from the parents to the offspring: the same set of 
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genes can be responsible for the emotional susceptibility of the individual and, if 
present in the parents as well, also for the invalidating environment that then creates a 
chaotic family dynamic. The mystery resides in the question of what is the cause and 
what is the consequence: either BPD emerges as a product of childhood maltreatment, 
or the maltreatment itself is the result of malfunctioning personality traits present both 
in the child and her parents. These traits correlate with poor parenting and, if 
genetically mediated, can explain the emotional liability present in the child.17 
The relationship between BPD and traumatic personal experiences underlines the 
importance of psychotherapy in the approach of the patient, with emotional regulation 
strategies being helpful in maintaining functioning and reducing distress.39 On the other 
hand, its social sensibility also points out the significance of sociotherapy.3 As discussed, 
a well-structured social context can help the individual in coping with personal 
disadvantages and adverse environments, especially in the presence of an unstable 
family context.16 
This work has a few limitations that should be addressed. First, the search 
conducted used terms contained in the abstracts and not MeSH terms. This is both a 
limitation and a strength, because if on one hand it may have precluded some articles 
without specific words in the abstract (but with the correct MeSH term) from the study, 
it also assured that studies regarding borderline personality traits and associated 
features, and not necessarily the disorder, could be included. Second, by limiting the 
initial search to works published in the year 2000 or after, there may have been 
important research that was not included merely because of the published date. 
Although there was an attempt to include such works on the second research stage 
(after reading the first 28 articles and identifying frequently quoted works), there is no 
guarantee as to whether there was any vital information lost in the process. A possible 
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strength should also be mentioned: because of the search for articles including “gene 
environment personality disorders” in the abstract and “gene environment personality” 
in the title, works regarding more than one PD could also be included. For this reason, I 
was able to retrieve important information about possible endophenotypes 
encompassing not only BPD but also other disorders. 
Torgersen stated that the only safe way to infer about gene-environment 
interactions is by having experimental control over the environment.17  Future 
investigations in this field should be performed using twin and family studies with large 
samples so as to increase statistical power, and preferably controlling for possible 
environmental confounding factors. Longitudinal studies are preferred to cross-
sectional studies in order to safely state causality, and community samples are favored 
because of the known social sensitivity of BPD. Finally, clinical interviews are the ideal 
method to assess BPD scores, and special attention must be paid to potential informant 
biases regarding past events such as childhood abuse, neglect or trauma. 
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